DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Active ingredient: Levorphanol - Brands, Medical Use, Clinical Data

Brands, Medical Use, Clinical Data

Drug Category

  • Narcotics
  • Analgesics, Opioid

Dosage Forms

  • Tablet

Brands / Synonyms

Antalgin; Aromarone; Cetarin; Dea No. 9220; Dea No. 9733; Dromoran; Lemoran; Levo-Dromoran; Levorfanol [Inn-Spanish]; Levorfanolo [Dcit]; Levorphan; Levorphanal; Levorphanol; Levorphanol Dl-Form; Levorphanol Tartrate; Levorphanolum [Inn-Latin]; Methorfinan [Czech]; Methorphinan; Orphan; Racemethorphanum; Racemic Dromoran; Racemorfano [Inn-Spanish]; Racemorphan; Racemorphan [Ban:Inn]; Racemorphane [Inn-French]; Racemorphanum [Inn-Latin]


For the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate


Levorphanol is a potent synthetic opioid analgesic indicated for the management of moderate to severe pain or as a preoperative medication where an opioid analgesic is appropriate. Levorphanol is similar to morphine in its actions, however it is up to 8 times more potent than morphine. Levorphanol produces a degree of respiratory depression similar to that produced by morphine at equianalgesic doses, and like many mu-opioid drugs, levorphanol produces euphoria or has a positive effect on mood in many individuals.

Mechanism of Action

Like other mu-agonist opioids it is believed to act at receptors in the periventricular and periaqueductal gray matter in both the brain and spinal cord to alter the transmission and perception of pain.


Levorphanol is well absorbed after PO administration with peak plasma concentrations occurring approximately 1 hour after dosing.


LD50=150 mg/kg (orally in rats). Signs of overdose include nausea, emesis, dizziness, respiratory depression, hypotension, urinary retention, cardiac arrhythmias, allergic reactions, skin rash, and uticaria.

Biotrnasformation / Drug Metabolism

Levorphanol is extensively metabolized in the liver and is eliminated as the glucuronide metabolite.


Levo-Dromoran is contraindicated in patients hypersensitive to levorphanol tartrate.


Drug Interactions

Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects. Respiratory depression, hypotension, and profound sedation or coma may occur. When such combined therapy is contemplated, the dose of one or both agents should be reduced. Although no interaction between MAO inhibitors and Levo-Dromoran has been observed, it is not recommended for use with MAO inhibitors.

Most cases of serious or fatal adverse events involving Levo-Dromoran reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of levorphanol with other drugs affecting respiration. The initial dose of levorphanol should be reduced by approximately 50% or more when it is given to patients along with another drug affecting respiration.

Interactions with Mixed Agonist/Antagonist Opioid Analgesics:   Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran. In opioid-dependent patients, mixed agonist/antagonist analgesics may precipitate withdrawal symptoms.

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017